Drug and Herb induced liver injury: a short review

Year 2017, , 24 - 29, 10.10.2017

Müzeyyen Çeliksöz , Buket Hün Gül Özhan

https://doi.org/10.5152/IstanbulJPharm.2017.005

Abstract

Chemical induced liver injury is a pathological condition caused by diver’s medications and other xenobiotics, leading to deficiencies in liver functions with the elimination of other diagnosis. Liver injury is prevalent in the world and can result in serious clinical outcome and has possibly fatal outcome. Chemical induced liver injury has an estimated annual incidence 10-15 per 10,000-100,000 patients received several prescription medications. The kind of liver injury are almost 10% cases with acute hepatitis, and is the most common cause of acute liver failure in the United States. Also, liver injury appeared after approval for marketing has restricted the use of many drugs (e.g., isoniazid, labetalol, and felbamate). Therefore, especially drug-induced liver injury is currently the major reason for discontinuation of a new compound in development or for withdrawal of a successfully launched drug from the market. In this review, we researched that mechanisms of liver injury with drugs and herbal preparations, and potential risks have been reported.

Keywords

Liver injury, hepatotoxicity, drug withdrawal

References

• Abdualmjid RJ, Sergi C (2013). Hepatotoxic botanicals-An evidence- based systematic review. J Pharm Pharm Sci 16(3): 376–404. [CrossRef ] • Aleo MD, Luo Y, Swiss R, Bonin PD, Potter DM, Will Y (2014). Human drug-induced liver injury severity is highly associated to dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology 60:1015–1022. [CrossRef ] • Björnsson E (2016). Hepatotoxicity by drugs: the most common ımplicated agents. Int J Mol Sci 17(2): 224. [CrossRef ] • Björnsson ES, Hoofnagle JH (2016). Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports. Hepatology 63(2): 590–603. [CrossRef ] • Boelsterli UA, Lim PLK (2007). Mitochondrial abnormalities-a link to idiosyncratic drug hepatotoxicity? Toxicol Appl Pharm 220(1): 92–107. [CrossRef ] • Bunchorntavakul C, Reddy KR (2013). Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther 37(1): 3–17. [CrossRef ] • Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J (2008). Causes, clinical features, and outcomes from a prospective study of drug-ınduced liver ınjury in the United States. Gastroenterology 135(6): 1924–1934. [CrossRef ] • Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI (2015). Druginduced liver injury: interactions between drug properties and host factors. J Hepatol 63(2): 503–514. [CrossRef ] • Clinical P (2009). Guidance for industry drug-induced liver injury: premarketing clinical evaluation. Drug Safety July, 28. Dağ MS, Aydınlı M, Öztürk ZA, Türkbeyler IH, Koruk I, Savaş MC, Koruk M, Kadayıfçı A (2014). Drug- and herb-induced liver injury: a case series from a single center. Turk J Gastroenterol 25: 41–45. [CrossRef ] • Daly AK (2012) Genetic polymorphisms affecting drug metabolism: Recent advances and clinical aspects. Adv. Pharmacol. 63: 137–167. [CrossRef ] • Dara L, Hewett J, Lim JK (2008). Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements. World J Gastroenterol 14(45): 6999–7004. [CrossRef ] • Federal Register. (2012). Patient protection and affordable care act; standards related to essential health benefits, actuarial value, and accreditation. Department of Health and Human Services, Part V, 77 (227): 70644–70676. • Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J (2009). Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct. Drug Safety 32(1): 55–68. [CrossRef ] • Garcia-Cortes M , Stephens C, Lucena M, Fernandez-Castaner A ,Andrade R.J (2011). Causality assessment methods in drug induced liver injury: Strengths and weaknesses. J Hepatol55: 683–691. [CrossRef ] • Gómez-Lechón MJ, Tolosa L, Donato MT (2015). Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs. J Appl Toxicol 36(6): 752-768. [CrossRef ] • Hussaini SH, Farrington EA (2014). Idiosyncratic drug-induced liver injury: an update on the 2007 overview. Expert Opin Drug Saf 13(1): 67–81. [CrossRef ] • Korth C (2014). Drug-induced hepatotoxicity of select herbal therapies. J Pharm Pract 27(6): 567–72. [CrossRef ] • Köck K, Ferslew BC, Netterberg I, Yang K, Urban TJ, Swaan PW, Stewart PW, Brouwer KL. (2014). Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab Dispos 42: 665–674. [CrossRef ] • Kramer JR, Giordano TP, Souchek J, El-Serag HB. (2005). Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol 42(3): 309–314. [CrossRef ] • Larrey D, Vial T, Pauwels A (1992). Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med 117: 129–32 [CrossRef ] • Larrey D, Faure S (2011). Herbal medicine hepatotoxicity: a new step with development of specific biomarkers. J Hepatol 54(4): 599–601. [CrossRef ] • Lee WM (2003). Drug-induced hepatotoxicity. N Eng J Med 349: 474–485. [CrossRef ] • Navarro VJ, Lucena MI (2014). Hepatotoxicity induced by herbal and dietary supplements. Semin Liver Dis 34(2): 172–193. [CrossRef ] • Njoku DB (2014). Drug-induced hepatotoxicity: metabolic, genetic and immunological basis. Int J Mol Sci 15(4): 6990–7003. [CrossRef ] • Oh SJ, Cho JH, Son CG (2015). Systematic review of the incidence of herbal drug-induced liver injury in Korea. J Ethnopharmacol 159: 253–256. [CrossRef ] • Russo MW, Galanko JA, Shrestha R (2004). Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 10(10) :18-235. [CrossRef ] • Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, Lemoine A, Hillon P (2002). Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36(2): 451–455. [CrossRef ] • Spengler U, Lichterfeld M, Rockstroh JK (2002). Antiretroviral drug toxicity-a challenge for the hepatologist? J Hepatol 36(2): 283–294. [CrossRef ] • Suk KT, Kim DJ (2012). Drug-induced liver injury: present and future. Clin Mol Hepatol 18(3): 249. [CrossRef ] • Stepan AF, Walker DP, Bauman J, Price DA, Baillie TA, Kalgutkar AS (2011). Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol 24:1345–1410. [CrossRef ] • Temple R (2006). Hy’s law : predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 15(4): 241–243. [CrossRef ] • Teschke R, Eickhoff A (2015). Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps. Front Pharmacol 6: 1–40. [CrossRef ] • Teschke R, Schwarzenboeck A, Eickhoff A, Frenzel C, Wolff A, Schulze J. (2013). Clinical and causality assessment in herbal hepatotoxicity. Expert Opin Drug Saf 12(3): 339–366. [CrossRef ] • Vree JM, Jacquemin E, Sturm E, Cresteil D, Bosma PJ, Aten J, Deleuze JF, Desrochers M, Burdelski M, Bernard O, Elferink RPJO, Hadchouel M (1998). Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci USA 95: 282–287. [CrossRef ] • Wu CP, Hsieh CH, Wu YS (2011). The emergence of drug transporter- mediated multidrug resistance to cancer chemotherapy. Mol Pharm 8: 1996–2011. [CrossRef ]